Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. Salmon-Céron D, et al. Among authors: boukli n. AIDS. 2000 May 26;14(8):1041-9. doi: 10.1097/00002030-200005260-00017. AIDS. 2000. PMID: 10853987 Clinical Trial.
Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy.
Mazeron MC, Fillet AM, Salmon D, Boukli N, Houhou N, Sénéchal B, Matheron S, Gozlan J, Leport C, Katlama C, Scieux C, Imbert BM, Deny P, Bour JB, Freymuth F, Chanzy B, Chaput S, Costagliola D; Predivir Study Group. Mazeron MC, et al. Among authors: boukli n. AIDS. 2003 Mar 28;17(5):784-6. doi: 10.1097/00002030-200303280-00029. AIDS. 2003. PMID: 12646814 No abstract available.
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, Chaix ML; AC43 ANRS Resistance Group. Visseaux B, et al. J Antimicrob Chemother. 2020 Jan 1;75(1):183-193. doi: 10.1093/jac/dkz404. J Antimicrob Chemother. 2020. PMID: 31641777
High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies.
Boukli N, Le Mene M, Schnuriger A, Cuervo NS, Laroche C, Morand-Joubert L, Gozlan J. Boukli N, et al. J Clin Microbiol. 2020 Oct 21;58(11):e01352-20. doi: 10.1128/JCM.01352-20. Print 2020 Oct 21. J Clin Microbiol. 2020. PMID: 32848041 Free PMC article. No abstract available.
Caution in interpretation of SARS-CoV-2 quantification based on RT-PCR cycle threshold value.
Schnuriger A, Perrier M, Marinho V, Michel Y, Saloum K, Boukli N, Lambert-Niclot S, Amiel C, Fofana DB, Gozlan J, Morand-Joubert L. Schnuriger A, et al. Among authors: boukli n. Diagn Microbiol Infect Dis. 2021 Jul;100(3):115366. doi: 10.1016/j.diagmicrobio.2021.115366. Epub 2021 Mar 4. Diagn Microbiol Infect Dis. 2021. PMID: 33756311 Free PMC article.
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
Launay O, Roudière L, Boukli N, Dupont B, Prévoteau du Clary F, Patey O, David F, Lortholary O, Devidas A, Piketty C, Rey E, Urbinelli R, Allaert FA, Tréluyer JM, Caumes E; Viramune-Zyrtec Study Group. Launay O, et al. Among authors: boukli n. Clin Infect Dis. 2004 Apr 15;38(8):e66-72. doi: 10.1086/382677. Epub 2004 Mar 29. Clin Infect Dis. 2004. PMID: 15095233 Clinical Trial.
53 results